← Leaderboards
Sudha B Biddinger
Boston Children'S Hospital
$16,178,424
Attributed
$16,694,904
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,694,904 · 9
By mechanism
R01$15,109,993 · 5
T32$923,719 · 1
K08$391,844 · 1
R03$169,348 · 1
R56$100,000 · 1
Top collaborators
- Gokhan S Hotamisligil5 shared
- Chih-Hao Lee2 shared
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Sanjay Srivastava$27,960,573
- Hong Chen$23,928,447
- John Y-J Shyy$24,226,917
- Jinjun Shi$13,516,816
- Denisa D Wagner$33,479,534
Others in their field
Top investigators on “Liver”
- David Heimbrook · Leidos Biomedical Research, Inc.$183,557,534
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Richard Douglas Moore · Johns Hopkins University$59,048,354
- Paul M. Ridker · Brigham And Women'S Hospital$55,416,022
- Michael S. Saag · University Of Alabama At Birmingham$50,288,385
- Mark A Kay · Stanford University$49,905,067
Research focus
LiverPreventCholesterolInsulinPathogenesisHepaticKnock-OutInsightDiabetes MellitusDyslipidemiasHepatocyteAtherosclerosisMetabolismMediatingMouse ModelHyperglycemiaInsulin ReceptorInsulin ResistancePhysiologicalCardiovascular DiseasesTranscription FactorGenesGenetic TranscriptionInsulin Signaling
Grant awards (43)
Novel Targets for Reducing Atherosclerosis in Type 1 Diabetes$694,247
R01 · FY2025 · HL · contact PI
The Role of Tcf7l2 in maintaining liver zonation and metabolic homeostasis$526,737
R01 · FY2025 · DK · contact PI
Insulin Regulation of Hepatic Function via Zone-Specific Transcriptional Programs$500,253
R01 · FY2025 · DK · contact PI
Training Program in Molecular Metabolism$200,250
T32 · FY2025 · DK
Pathogenesis of Dyslipidemia and Atherosclerosis in the Diabetic State$693,205
R01 · FY2024 · HL · contact PI
Novel Targets for Reducing Atherosclerosis in Type 1 Diabetes$669,816
R01 · FY2024 · HL · contact PI
The Role of Tcf7l2 in maintaining liver zonation and metabolic homeostasis$451,852
R01 · FY2024 · DK · contact PI
Training Program in Molecular Metabolism$196,459
T32 · FY2024 · DK
Pathogenesis of Dyslipidemia and Atherosclerosis in the Diabetic State$704,867
R01 · FY2023 · HL · contact PI
Novel Targets for Reducing Atherosclerosis in Type 1 Diabetes$683,486
R01 · FY2023 · HL · contact PI
Insulin Regulation of Hepatic Function via Zone-Specific Transcriptional Programs$500,167
R01 · FY2023 · DK · contact PI
The Role of Tcf7l2 in maintaining liver zonation and metabolic homeostasis$465,289
R01 · FY2023 · DK · contact PI
Training Program in Molecular Metabolism$199,284
T32 · FY2023 · DK
Novel Targets for Reducing Atherosclerosis in Type 1 Diabetes$687,026
R01 · FY2022 · HL · contact PI
Pathogenesis of Dyslipidemia and Atherosclerosis in the Diabetic State$679,451
R01 · FY2022 · HL · contact PI
Insulin Regulation of Hepatic Function via Zone-Specific Transcriptional Programs$560,465
R01 · FY2022 · DK · contact PI
Training Program in Molecular Metabolism$195,169
T32 · FY2022 · DK
Pathogenesis of Dyslipidemia and Atherosclerosis in the Diabetic State$651,929
R01 · FY2021 · HL · contact PI
Insulin Regulation of Hepatic Function via Zone-Specific Transcriptional Programs$632,478
R01 · FY2021 · DK · contact PI
Training Program in Molecular Metabolism$132,557
T32 · FY2021 · DK
Dissecting the Role of Trimethylamine N-oxide in Chronic Kidney Disease Development$100,000
R56 · FY2021 · DK · contact PI
Pathogenesis of Dyslipidemia and Atherosclerosis in the Diabetic State$442,500
R01 · FY2020 · HL · contact PI
Pathogenesis of Dyslipidemia and Atherosclerosis in the Diabetic State$442,500
R01 · FY2019 · HL · contact PI
Pathogenesis of Dyslipidemia and Atherosclerosis in the Diabetic State$442,500
R01 · FY2018 · HL · contact PI
Pathogenesis of Dyslipidemia and Atherosclerosis in the Diabetic State$442,500
R01 · FY2017 · HL · contact PI
Pathogenesis of Dyslipidemia and Atherosclerosis in the Diabetic State$442,500
R01 · FY2016 · HL · contact PI
Pathogenesis of Dyslipidemia and Atherosclerosis in the Diabetic State$501,518
R01 · FY2015 · HL · contact PI
Control of lipid metabolism in insulin resistant states$378,450
R01 · FY2015 · DK · contact PI
Pathogenesis of Dyslipidemia and Atherosclerosis in the Diabetic State$499,125
R01 · FY2014 · HL · contact PI
Control of lipid metabolism in insulin resistant states$378,450
R01 · FY2014 · DK · contact PI
Pathogenesis of Dyslipidemia and Atherosclerosis in the Diabetic State$11,741
R01 · FY2014 · HL · contact PI
Pathogenesis of Dyslipidemia and Atherosclerosis in the Diabetic State$414,120
R01 · FY2013 · HL · contact PI
Control of lipid metabolism in insulin resistant states$365,205
R01 · FY2013 · DK · contact PI
Pathogenesis of Dyslipidemia and Atherosclerosis in the Diabetic State$435,000
R01 · FY2012 · HL · contact PI
Control of lipid metabolism in insulin resistant states$378,450
R01 · FY2012 · DK · contact PI
Pathogenesis of Dyslipidemia and Atherosclerosis in the Diabetic State$434,166
R01 · FY2011 · HL · contact PI
The role of insulin signaling in the dyslipidemia of the metabolic syndrome$84,893
R03 · FY2010 · DK · contact PI
The Interaction Between Hepatic Insulin Resistance and Cholesterol Metabolism$10,145
K08 · FY2010 · DK · contact PI
The Interaction Between Hepatic Insulin Resistance and Cholesterol Metabolism$127,233
K08 · FY2009 · DK · contact PI
The role of insulin signaling in the dyslipidemia of the metabolic syndrome$73,175
R03 · FY2009 · DK · contact PI
The role of insulin signaling in the dyslipidemia of the metabolic syndrome$11,280
R03 · FY2009 · DK · contact PI
The Interaction Between Hepatic Insulin Resistance and Cholesterol Metabolism$127,233
K08 · FY2008 · DK · contact PI
The Interaction Between Hepatic Insulin Resistance and Cholesterol Metabolism$127,233
K08 · FY2007 · DK · contact PI